Advertisement

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Published:August 24, 2018DOI:https://doi.org/10.1016/j.clgc.2018.08.001

      Abstract

      Background

      The optimal timing of targeted therapy (TT) initiation for metastatic renal-cell carcinoma (mRCC) is not clear. We used a nationwide cancer registry to determine clinical and social factors associated with delayed TT and to evaluate the association of a delayed approach with overall survival (OS).

      Patients and Methods

      We performed a retrospective observational study utilizing the National Cancer Data Base from 2006 to 2012 for patients diagnosed with mRCC (clear-cell histology) treated with cytoreductive nephrectomy and TT. Time to initiation of TT was defined as early (within 2 months), moderately delayed (2-4 months), delayed (4-6 months), and late (> 6 months).

      Results

      Of the 2716 patients included in the analysis, the median (interquartile range) time from diagnosis to initiation of TT was 2.1 (1.3-3.23) months. A total of 1255 patients (46.2%) had early TT, 1072 patients (39.5%) had moderately delayed TT, 284 patients (10.5%) had delayed TT, and 105 patients (3.9%) had late TT. Delay in TT initiation was not independently associated with OS in multivariable analysis. The time interval from diagnosis to TT initiation was not correlated with time from initiation of TT to death (r = 0.04, P = .08).

      Conclusion

      We found that delayed initiation of TT was not an independent predictor of worse OS. Although this study is subject to limitations of observation study design and selection bias, the results are consistent with the notion that in carefully selected patients, outcomes might not be compromised with initial observation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2017.
        CA Cancer J Clin. 2017; 67: 7-30
        • Kane C.J.
        • Mallin K.
        • Ritchey J.
        • Cooperberg M.R.
        • Carroll P.R.
        Renal cell cancer stage migration: analysis of the National Cancer Data Base.
        Cancer. 2008; 113: 78-83
        • Pantuck A.J.
        • Zisman A.
        • Belldegrun A.S.
        The changing natural history of renal cell carcinoma.
        J Urol. 2001; 166: 1611-1623
        • National Comprehensive Cancer Network
        NCCN clinical practice guidelines: kidney cancer, version 2.2017.
        (Available at:)
        • Choueiri T.K.
        • Motzer R.J.
        Systemic therapy for metastatic renal-cell carcinoma.
        N Engl J Med. 2017; 376: 354-366
        • Heng D.Y.
        • Xie W.
        • Regan M.M.
        • et al.
        Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study.
        J Clin Oncol. 2009; 27: 5794-5799
        • Motzer R.J.
        • Bacik J.
        • Murphy B.A.
        • Russo P.
        • Mazumdar M.
        Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
        J Clin Oncol. 2002; 20: 289-296
        • Wong A.S.
        • Chong K.T.
        • Heng C.T.
        • et al.
        Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma.
        Urol Oncol. 2009; 27: 149-154
        • Fisher R.
        • Pender A.
        • Thillai K.
        • et al.
        Observation as a treatment strategy for advanced renal cell carcinoma—a call for prospective validation.
        Front Oncol. 2012; 2: 155
        • Matsubara N.
        • Mukai H.
        • Naito Y.
        • Itoh K.
        • Komai Y.
        • Sakai Y.
        First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
        Urology. 2013; 82: 118-123
        • Park I.
        • Lee J.L.
        • Ahn J.H.
        • et al.
        Active surveillance for metastatic or recurrent renal cell carcinoma.
        J Cancer Res Clin Oncol. 2014; 140: 1421-1428
        • Rini B.I.
        • Dorff T.B.
        • Elson P.
        • et al.
        Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.
        Lancet Oncol. 2016; 17: 1317-1324
        • Xu F.
        • Rimm A.A.
        • Fu P.
        • Krishnamurthi S.S.
        • Cooper G.S.
        The impact of delayed chemotherapy on its completion and survival outcomes in stage II colon cancer patients.
        PLoS One. 2014; 9: e107993
        • Chavez-MacGregor M.
        • Clarke C.A.
        • Lichtensztajn D.Y.
        • Giordano S.H.
        Delayed initiation of adjuvant chemotherapy among patients with breast cancer.
        JAMA Oncol. 2016; 2: 322-329
        • Bilimoria K.Y.
        • Stewart A.K.
        • Winchester D.P.
        • Ko C.Y.
        The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.
        Ann Surg Oncol. 2008; 15: 683-690
        • Boffa D.J.
        • Rosen J.E.
        • Mallin K.
        • et al.
        Using the National Cancer Data Base for outcomes research: a review.
        JAMA Oncol. 2017;
        • American College of Surgeons
        Facility Oncology Registry Data Standards (FORDS): revised for 2016.
        (Available at:)
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125-134
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115-124
        • Hanna N.
        • Sun M.
        • Meyer C.P.
        • et al.
        Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study.
        J Clin Oncol. 2016; 34: 3267-3275
        • Mejean A.
        • Ravaud A.
        • Thezenas S.
        • et al.
        Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma.
        N Engl J Med. 2018; 379: 417-427
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45: 613-619
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
        J Clin Oncol. 2009; 27: 3312-3318
        • Motzer R.J.
        • Escudier B.
        • Oudard S.
        • et al.
        Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
        Lancet. 2008; 372: 449-456
        • Ardeshna K.M.
        • Smith P.
        • Norton A.
        • et al.
        Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
        Lancet. 2003; 362: 516-522
        • Lenis A.T.
        • Donin N.M.
        • Johnson D.C.
        • et al.
        Adjuvant therapy for high-risk localized kidney cancer—emerging evidence and future clinical trials.
        J Urol. 2018; 199: 43-52
        • Eisen T.
        • Sternberg C.N.
        • Robert C.
        • et al.
        Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
        J Natl Cancer Inst. 2012; 104: 93-113
        • Geynisman D.M.
        • Hu J.C.
        • Liu L.
        • Tina Shih Y.C.
        Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
        Clin Genitourin Cancer. 2015; 13: e93-e100